COVID-19 caused by SARS-CoV-2 infection, is a contagious disease leading to the ongoing pandemic. D-dimer testing, a sensitive parameter to investigate hemostasis, could be helpful to rapidly identify COVID-19 patients with severe illness, pulmonary complications, and risk of thromboembolism. A recent meta-analysis has shown that patients with severe COVID-19 have higher D-dimer concentrations. The risk stratification assisted by D-dimer testing and early treatment might reduce COVID-19-related morbidityand mortality[2,3]. As a sensitive monitoring index, D-dimer could provide valuable clinical information in the management and prognosis prediction of COVID-19 patients.
Mindray's Biochemistry D-dimer Solution
Mindray biochemistry D-Dimer assay with particle-enhanced immunoturbidimetric method can give quantitative determination of cross-linked ﬁbrin degradation products (D-dimers).
Key benefits of Mindray D-dimer tests:
Ready to use reagent: fully automated processing without manual working solution preparation
Stable reagents: 4 weeks on-board stability at 2–8°C
Wide linearity range (0.5~48 μg/mL): reduce sample dilution and improve efficiency
Mindray's flagship stand-alone chemistry analyzers:
System function: automatic, random access, STAT sample priority
Throughput: constant 420 photometric tests per hour, up to 626 tests per hour with ISE
Reagent/sample tray: 102 sample positions, 92 reagent positions with 24-hour refrigeration (2~8°C)
System function: automatic, random access, bench-top, STAT sample priority
Throughput: constant 240 photometric tests per hour, up to 400 T/H with ISE
Reagent/sample tray: 50 to 100 positions for reagents and 50 to 100 positions for samples in 24-hour refrigerated compartment (2~12°C)
 Panagiotis Paliogiannis, Arduino Aleksander Mangoni, Paola Dettori3, et al.D-Dimer Concentrations and COVID-19 Severity: A Systematic Review andMeta-Analysis. Public Health, 04 August 2020.
 Dawei Wang, Bo Hu, et al. ClinicalChatacteristics of 138 hospitalized patients with 2019 novelCoronavirus-Infected Pneumonia in Wuhan,China[J]. JAMA. 2020.
 Fei Zhou., MD,a., Ting Yu., MD,b.Clinical course and risk factors for mortality of adult inpatients withCOVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 28March-3 April; 395(10229): 1054–1062.